Multi-parametric thrombus profiling microfluidics detects intensified biomechanical thrombogenesis associated with hypertension and aging.

Humans Thrombosis / metabolism Hypertension / physiopathology Aging Male Aged Female Middle Aged Microfluidics / methods Platelet Aggregation Platelet Glycoprotein GPIb-IX Complex / metabolism Biomechanical Phenomena Adult Blood Platelets / metabolism

Journal

Nature communications

ISSN: 2041-1723

Titre abrégé: Nat Commun

Pays: England

ID NLM: 101528555

Informations de publication

Date de publication:
21 Oct 2024

Historique:

received: 03 01 2024

accepted: 30 09 2024

medline: 22 10 2024

pubmed: 22 10 2024

entrez: 21 10 2024

Statut: epublish

Résumé

Arterial thrombosis is a leading cause of death and disability worldwide with no effective bioassay for clinical prediction. As a symbolic feature of arterial thrombosis, severe stenosis in the blood vessel creates a high-shear, high-gradient flow environment that facilitates platelet aggregation towards vessel occlusion. Here, we present a thrombus profiling assay that monitors the multi-dimensional attributes of thrombi forming in such biomechanical conditions. Using this assay, we demonstrate that different receptor-ligand interactions contribute distinctively to the composition and activation status of the thrombus. Our investigation into hypertensive and older individuals reveals intensified biomechanical thrombogenesis and multi-dimensional thrombus profile abnormalities, endorsing the diagnostic potential of the assay. Furthermore, we identify the hyperactivity of GPIbα-integrin α

Identifiants

DOI: 10.1038/s41467-024-53069-9 PMID: 39433750

pubmed: 39433750

doi: 10.1038/s41467-024-53069-9

pii: 10.1038/s41467-024-53069-9

doi:

Substances chimiques

Platelet Glycoprotein GPIb-IX Complex 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

9067

Subventions

Organisme : U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI)

ID : R00HL153678

Organisme : U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging)

ID : P30-AG024832

Organisme : American Heart Association (American Heart Association, Inc.)

ID : 20POST35080023

Organisme : U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS)

ID : 1R01GM152812

Organisme : National Science Foundation (NSF)

ID : DMS-1953189, CCF-2007823 and DMS-2210775

Informations de copyright

Références

Benjamin, E. J. et al. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation 139, e56–e528 (2019).

pubmed: 30700139 doi: 10.1161/CIR.0000000000000659

Springer, T. A. von Willebrand factor, Jedi knight of the bloodstream. Blood 124, 1412–1425 (2014).

pubmed: 24928861 pmcid: 4148764 doi: 10.1182/blood-2014-05-378638

Akturk, I. F. et al. Hypertension as a risk factor for aspirin and clopidogrel resistance in patients with stable coronary artery disease. Clin. Appl. Thromb. Hemost. 20, 749–754 (2014).

pubmed: 23493759 doi: 10.1177/1076029613481102

Liu, X. F. et al. Prevalence of and risk factors for aspirin resistance in elderly patients with coronary artery disease. J. Geriatr. Cardiol. 10, 21–27, (2013).

pubmed: 23610570 pmcid: 3627718

Jackson, S. P. Arterial thrombosis–insidious, unpredictable and deadly. Nat. Med. 17, 1423–1436 (2011).

pubmed: 22064432 doi: 10.1038/nm.2515

Previtali, E., Bucciarelli, P., Passamonti, S. M. & Martinelli, I. Risk factors for venous and arterial thrombosis. Blood Transfus. 9, 120–138, (2011).

pubmed: 21084000 pmcid: 3096855

Govender, R. D., Al-Shamsi, S., Soteriades, E. S. & Regmi, D. Incidence and risk factors for recurrent cardiovascular disease in middle-eastern adults: a retrospective study. BMC Cardiovasc. Disord. 19, 253 (2019).

pubmed: 31711429 pmcid: 6849175 doi: 10.1186/s12872-019-1231-z

Zhang, Y. et al. Emerging microfluidic approaches for platelet mechanobiology and interplay with circulatory systems. Front. Cardiovasc. Med. 8, 766513 (2021).

pubmed: 34901226 pmcid: 8655735 doi: 10.3389/fcvm.2021.766513

Zhang, Y., Jiang, F., Chen, Y. & Ju, L. A. Platelet mechanobiology inspired microdevices: from hematological function tests to disease and drug screening. Front. Pharmacol. 12, 779753 (2021).

pubmed: 35126120 doi: 10.3389/fphar.2021.779753

Nesbitt, W. S. et al. A shear gradient-dependent platelet aggregation mechanism drives thrombus formation. Nat. Med. 15, 665–673 (2009).

pubmed: 19465929 doi: 10.1038/nm.1955

Chen, Y. & Ju, L. A. Biomechanical thrombosis: the dark side of force and dawn of mechano-medicine. Stroke Vasc. Neurol. 5, 185–197 (2020).

pubmed: 32606086 doi: 10.1136/svn-2019-000302

Chen, Y. et al. An integrin alphaIIbbeta3 intermediate affinity state mediates biomechanical platelet aggregation. Nat. Mater. 18, 760–769 (2019).

pubmed: 30911119 pmcid: 6586518 doi: 10.1038/s41563-019-0323-6

Fu, H. et al. Flow-induced elongation of von Willebrand factor precedes tension-dependent activation. Nat. Commun. 8, 324 (2017).

pubmed: 28831047 pmcid: 5567343 doi: 10.1038/s41467-017-00230-2

Yago, T. et al. Platelet glycoprotein Ibalpha forms catch bonds with human WT vWF but not with type 2B von Willebrand disease vWF. J. Clin. Investig. 118, 3195–3207 (2008).

pubmed: 18725999 pmcid: 2518822

Ju, L. et al. Compression force sensing regulates integrin alphaIIbbeta3 adhesive function on diabetic platelets. Nat. Commun. 9, 1087 (2018).

pubmed: 29540687 pmcid: 5852038 doi: 10.1038/s41467-018-03430-6

Zhao, W. et al. Piezo1 initiates platelet hyperreactivity and accelerates thrombosis in hypertension. J. Thromb. Haemost. https://doi.org/10.1111/jth.15504 (2021).

Ju, L. A. et al. Microfluidic post method for 3-dimensional modeling of platelet-leukocyte interactions. Analyst 147, 1222–1235 (2022).

pubmed: 35212697 doi: 10.1039/D2AN00270A

Zhang, X. F. & Cheng, X. Platelet mechanosensing axis revealed. Nat. Mater. 18, 661–662 (2019).

pubmed: 31217554 doi: 10.1038/s41563-019-0393-5

Yakusheva, A. A. et al. Traumatic vessel injuries initiating hemostasis generate high shear conditions. Blood Adv. 6, 4834–4846 (2022).

pubmed: 35728058 pmcid: 9631664 doi: 10.1182/bloodadvances.2022007550

Panteleev, M. A. et al. Wall shear rates in human and mouse arteries: standardization of hemodynamics for in vitro blood flow assays: communication from the ISTH SSC subcommittee on biorheology. J. Thromb. Haemost. 19, 588–595 (2021).

pubmed: 34396692 doi: 10.1111/jth.15174

Dent, J. A., Galbusera, M. & Ruggeri, Z. M. Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit. J. Clin. Investig. 88, 774–782 (1991).

pubmed: 1909351 pmcid: 295461 doi: 10.1172/JCI115376

Kamath, S., Blann, A. D. & Lip, G. Y. Platelet activation: assessment and quantification. Eur. Heart J. 22, 1561–1571 (2001).

pubmed: 11492985 doi: 10.1053/euhj.2000.2515

Schoenwaelder, S. M. et al. Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood 114, 663–666 (2009).

pubmed: 19387006 doi: 10.1182/blood-2009-01-200345

Brazilek, R. J. et al. Application of a strain rate gradient microfluidic device to von Willebrand’s disease screening. Lab Chip 17, 2595–2608 (2017).

pubmed: 28660968 doi: 10.1039/C7LC00498B

Merten, M., Chow, T., Hellums, J. D. & Thiagarajan, P. A new role for P-selectin in shear-induced platelet aggregation. Circulation 102, 2045–2050 (2000).

pubmed: 11044418 doi: 10.1161/01.CIR.102.17.2045

Deng, W. et al. Platelet clearance via shear-induced unfolding of a membrane mechanoreceptor. Nat. Commun. 7, 12863 (2016).

pubmed: 27670775 pmcid: 5052631 doi: 10.1038/ncomms12863

Hu, H. et al. Platelet-leukocyte aggregation under shear stress: differential involvement of selectins and integrins. Thromb. Haemost. 90, 679–687 (2003).

pubmed: 14515189 doi: 10.1160/TH03-05-0274

Roka-Moiia, Y. et al. Platelet activation via shear stress exposure induces a differing pattern of biomarkers of activation versus biochemical agonists. Thromb. Haemost. 120, 776–792 (2020).

pubmed: 32369849 pmcid: 8577487 doi: 10.1055/s-0040-1709524

Pang, A. et al. Shear-induced integrin signaling in platelet phosphatidylserine exposure, microvesicle release, and coagulation. Blood 132, 533–543 (2018).

pubmed: 29853537 pmcid: 6073322 doi: 10.1182/blood-2017-05-785253

Chen, W. et al. Inhibiting GPIbalpha shedding preserves post-transfusion recovery and hemostatic function of platelets after prolonged storage. Arterioscler. Thromb. Vasc. Biol. 36, 1821–1828 (2016).

pubmed: 27417583 pmcid: 5001887 doi: 10.1161/ATVBAHA.116.307639

Arrebola, M. M. et al. In vitro effects of clopidogrel on the platelet-subendothelium interaction, platelet thromboxane and endothelial prostacyclin production, and nitric oxide synthesis. J. Cardiovasc. Pharm. 43, 74–82 (2004).

doi: 10.1097/00005344-200401000-00012

Li, M., Hotaling, N. A., Ku, D. N. & Forest, C. R. Microfluidic thrombosis under multiple shear rates and antiplatelet therapy doses. PLoS ONE 9, e82493 (2014).

pubmed: 24404131 pmcid: 3880267 doi: 10.1371/journal.pone.0082493

Kanaji, S. et al. Humanized GPIbalpha-von Willebrand factor interaction in the mouse. Blood Adv. 2, 2522–2532 (2018).

pubmed: 30287479 pmcid: 6177644 doi: 10.1182/bloodadvances.2018023507

Yuan, Y. et al. The von Willebrand factor-glycoprotein Ib/V/IX interaction induces actin polymerization and cytoskeletal reorganization in rolling platelets and glycoprotein Ib/V/IX-transfected cells. J. Biol. Chem. 274, 36241–36251 (1999).

pubmed: 10593912 doi: 10.1074/jbc.274.51.36241

De Marco, L., Girolami, A., Zimmerman, T. S. & Ruggeri, Z. M. von Willebrand factor interaction with the glycoprotein IIb/IIa complex. Its role in platelet function as demonstrated in patients with congenital afibrinogenemia. J. Clin. Investig. 77, 1272–1277 (1986).

pubmed: 3007578 pmcid: 424474 doi: 10.1172/JCI112430

Berliner, S., Niiya, K., Roberts, J. R., Houghten, R. A. & Ruggeri, Z. M. Generation and characterization of peptide-specific antibodies that inhibit von Willebrand factor binding to glycoprotein IIb-IIIa without interacting with other adhesive molecules. Selectivity is conferred by Pro1743 and other amino acid residues adjacent to the sequence Arg1744-Gly1745-Asp1746. J. Biol. Chem. 263, 7500–7505 (1988).

pubmed: 2453507 doi: 10.1016/S0021-9258(18)68526-6

Lengweiler, S. et al. Preparation of monoclonal antibodies to murine platelet glycoprotein IIb/IIIa (alphaIIbbeta3) and other proteins from hamster-mouse interspecies hybridomas. Biochem. Biophys. Res. Commun. 262, 167–173 (1999).

pubmed: 10448087 doi: 10.1006/bbrc.1999.1172

Felding-Habermann, B., Ruggeri, Z. M. & Cheresh, D. A. Distinct biological consequences of integrin alpha v beta 3-mediated melanoma cell adhesion to fibrinogen and its plasmic fragments. J. Biol. Chem. 267, 5070–5077 (1992).

pubmed: 1531979 doi: 10.1016/S0021-9258(18)42731-7

Rooney, M. M., Farrell, D. H., van Hemel, B. M., de Groot, P. G. & Lord, S. T. The contribution of the three hypothesized integrin-binding sites in fibrinogen to platelet-mediated clot retraction. Blood 92, 2374–2381 (1998).

pubmed: 9746777 doi: 10.1182/blood.V92.7.2374

Liu, Q., Matsueda, G., Brown, E. & Frojmovic, M. The AGDV residues on the gamma chain carboxyl terminus of platelet-bound fibrinogen are needed for platelet aggregation. Biochim. Biophys. Acta 1343, 316–326 (1997).

pubmed: 9434121 doi: 10.1016/S0167-4838(97)00130-1

Coller, B. S. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J. Clin. Investig. 76, 101–108 (1985).

pubmed: 2991335 pmcid: 423718 doi: 10.1172/JCI111931

Kaul, D. K. et al. Monoclonal antibodies to alphaVbeta3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor. Blood 95, 368–374 (2000).

pubmed: 10627437 doi: 10.1182/blood.V95.2.368

Griffin, M. T., Zhu, Y., Liu, Z., Aidun, C. K. & Ku, D. N. Inhibition of high shear arterial thrombosis by charged nanoparticles. Biomicrofluidics 12, 042210 (2018).

pubmed: 29887934 pmcid: 5973895 doi: 10.1063/1.5025349

Wilkerson, W. R. & Sane, D. C. Aging and thrombosis. Semin. Thromb. Hemost. 28, 555–568 (2002).

pubmed: 12536349 doi: 10.1055/s-2002-36700

Tsao, C. W. et al. Heart disease and stroke statistics-2022 update: a report from the American Heart Association. Circulation 145, e153–e639 (2022).

pubmed: 35078371 doi: 10.1161/CIR.0000000000001052

Charles, S. The proof and measurement of association between two things. Am. J. Psychol. 15, 72–101 (1904).

doi: 10.2307/1412159

Kendall, M. G. A new measure of rank correlation. Biometrika 30, 81–93 (1938).

doi: 10.1093/biomet/30.1-2.81

Safford, M. M. et al. Association of race and sex with risk of incident acute coronary heart disease events. JAMA 308, 1768–1774, (2012).

pubmed: 23117777 pmcid: 3772637 doi: 10.1001/jama.2012.14306

Colantonio, L. D. et al. Black-White differences in incident fatal, nonfatal, and total coronary heart disease. Circulation 136, 152–166 (2017).

pubmed: 28696265 pmcid: 5551431 doi: 10.1161/CIRCULATIONAHA.116.025848

Mahalingam, A. et al. Numerical analysis of the effect of turbulence transition on the hemodynamic parameters in human coronary arteries. Cardiovasc. Diagn. Ther. 6, 208–220 (2016).

pubmed: 27280084 pmcid: 4880750 doi: 10.21037/cdt.2016.03.08

Ku, D. N. Blood flow in arteries. Annu. Rev. Fluid Mech. 29, 399–434 (1997).

doi: 10.1146/annurev.fluid.29.1.399

Chen, Y. et al. Fluorescence biomembrane force probe: concurrent quantitation of receptor-ligand kinetics and binding-induced intracellular signaling on a single cell. J. Vis. Exp. https://doi.org/10.3791/52975 (2015).

Chesla, S. E., Selvaraj, P. & Zhu, C. Measuring two-dimensional receptor-ligand binding kinetics by micropipette. Biophys. J. 75, 1553–1572 (1998).

pubmed: 9726957 pmcid: 1299830 doi: 10.1016/S0006-3495(98)74074-3

Ju, L. et al. Von Willebrand factor-A1 domain binds platelet glycoprotein Ibalpha in multiple states with distinctive force-dependent dissociation kinetics. Thromb. Res. 136, 606–612 (2015).

pubmed: 26213126 pmcid: 4553094 doi: 10.1016/j.thromres.2015.06.019

Ju, L., Chen, Y., Xue, L., Du, X. & Zhu, C. Cooperative unfolding of distinctive mechanoreceptor domains transduces force into signals. eLife 5, e15447 (2016).

pubmed: 27434669 pmcid: 5021522 doi: 10.7554/eLife.15447

Du, J., Kim, D., Alhawael, G., Ku, D. N. & Fogelson, A. L. Clot permeability, agonist transport, and platelet binding kinetics in arterial thrombosis. Biophys. J. 119, 2102–2115 (2020).

pubmed: 33147477 pmcid: 7732729 doi: 10.1016/j.bpj.2020.08.041

Wong, N. D. et al. Atherosclerotic cardiovascular disease risk assessment: an American Society for Preventive Cardiology clinical practice statement. Am. J. Prev. Cardiol. 10, 100335 (2022).

pubmed: 35342890 pmcid: 8943256 doi: 10.1016/j.ajpc.2022.100335

Anjum, M. et al. Stroke and bleeding risk in atrial fibrillation with CHA2DS2-VASC risk score of one: the Norwegian AFNOR study. Eur. Heart J. 45, 57–66 (2024).

pubmed: 37995254 doi: 10.1093/eurheartj/ehad659

Farrell, D. H., Thiagarajan, P., Chung, D. W. & Davie, E. W. Role of fibrinogen alpha and gamma chain sites in platelet aggregation. Proc. Natl Acad. Sci. USA 89, 10729–10732 (1992).

pubmed: 1438269 pmcid: 50415 doi: 10.1073/pnas.89.22.10729

Jackson, S. P. The growing complexity of platelet aggregation. Blood 109, 5087–5095 (2007).

pubmed: 17311994 doi: 10.1182/blood-2006-12-027698

Dai, K., Bodnar, R., Berndt, M. C. & Du, X. A critical role for 14-3-3zeta protein in regulating the VWF binding function of platelet glycoprotein Ib-IX and its therapeutic implications. Blood 106, 1975–1981 (2005).

pubmed: 15941906 pmcid: 1373670 doi: 10.1182/blood-2005-01-0440

Shen, B. et al. A directional switch of integrin signalling and a new anti-thrombotic strategy. Nature 503, 131–135 (2013).

pubmed: 24162846 pmcid: 3823815 doi: 10.1038/nature12613

Gkaliagkousi, E., Passacquale, G., Douma, S., Zamboulis, C. & Ferro, A. Platelet activation in essential hypertension: implications for antiplatelet treatment. Am. J. Hypertens. 23, 229–236 (2010).

pubmed: 20094035 doi: 10.1038/ajh.2009.247

Cattaneo, M. Resistance to anti-platelet agents. Thromb. Res. 127, S61–S63 (2011).

pubmed: 21262444 doi: 10.1016/S0049-3848(11)70017-2

Griendling, K. K. et al. Oxidative stress and hypertension. Circ. Res. 128, 993–1020 (2021).

pubmed: 33793335 pmcid: 8293920 doi: 10.1161/CIRCRESAHA.121.318063

Scherlinger, M., Richez, C., Tsokos, G. C., Boilard, E. & Blanco, P. The role of platelets in immune-mediated inflammatory diseases. Nat. Rev. Immunol. 23, 495–510 (2023).

pubmed: 36707719 doi: 10.1038/s41577-023-00834-4

Li, X. et al. Inflammation and aging: signaling pathways and intervention therapies. Signal Transduct. Target. Ther. 8, 239 (2023).

pubmed: 37291105 pmcid: 10248351 doi: 10.1038/s41392-023-01502-8

Schjoldager, K. T., Narimatsu, Y., Joshi, H. J. & Clausen, H. Global view of human protein glycosylation pathways and functions. Nat. Rev. Mol. Cell Biol. 21, 729–749 (2020).

pubmed: 33087899 doi: 10.1038/s41580-020-00294-x

Palmer, A. K. & Jensen, M. D. Metabolic changes in aging humans: current evidence and therapeutic strategies. J. Clin. Invest. https://doi.org/10.1172/JCI158451 (2022).

Shankar, A., Wang, J. J., Rochtchina, E. & Mitchell, P. Positive association between plasma fibrinogen level and incident hypertension among men: population-based cohort study. Hypertension 48, 1043–1049 (2006).

pubmed: 17000922 doi: 10.1161/01.HYP.0000245700.13817.3c

Hager, K., Felicetti, M., Seefried, G. & Platt, D. Fibrinogen and aging. Aging 6, 133–138 (1994).

Chung, T. et al. Platelet activation in acute pulmonary embolism. J. Thromb. Haemost. 5, 918–924 (2007).

pubmed: 17371486 doi: 10.1111/j.1538-7836.2007.02461.x

Gawaz, M., Geisler, T. & Borst, O. Current concepts and novel targets for antiplatelet therapy. Nat. Rev. Cardiol. 20, 583–599 (2023).

pubmed: 37016032 doi: 10.1038/s41569-023-00854-6

Topol, E. J. et al. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation 108, 399–406 (2003).

pubmed: 12874182 doi: 10.1161/01.CIR.0000084501.48570.F6

Chew, D. P., Bhatt, D. L., Sapp, S. & Topol, E. J. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 103, 201–206 (2001).

pubmed: 11208677 doi: 10.1161/01.CIR.103.2.201

Cox, D. et al. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes. J. Am. Coll. Cardiol. 36, 1514–1519 (2000).

pubmed: 11079651 doi: 10.1016/S0735-1097(00)00919-0

Lin, F. Y. et al. A general chemical principle for creating closure-stabilizing integrin inhibitors. Cell 185, 3533–3550.e3527 (2022).

pubmed: 36113427 pmcid: 9494814 doi: 10.1016/j.cell.2022.08.008

Reininger, A. J. et al. Mechanism of platelet adhesion to von Willebrand factor and microparticle formation under high shear stress. Blood 107, 3537–3545 (2006).

pubmed: 16449527 pmcid: 1895770 doi: 10.1182/blood-2005-02-0618

Lohmann, W. & Lohmann, C. Native fluorescence of platelets from patients with occlusive arterial disease. Biochem. Biophys. Res. Commun. 152, 1410–1415 (1988).

pubmed: 3377778 doi: 10.1016/S0006-291X(88)80442-X

Evans, E., Ritchie, K. & Merkel, R. Sensitive force technique to probe molecular adhesion and structural linkages at biological interfaces. Biophys. J. 68, 2580–2587 (1995).

pubmed: 7647261 pmcid: 1282168 doi: 10.1016/S0006-3495(95)80441-8